A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Terminated · Phase 2 · NCT05513703
Conditions: Non Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $2,746
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 9
About the trial
- Sponsor
- AbbVie
- Tested
- Telisotuzumab Vedotin (biological)
- Dates
- Started 2022-11-21; completion 2024-10-28
- Results posted
- Yes
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previousl…
From ClinicalTrials.gov, last updated 2025-10-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2,746 in research payments for this study in 2025 (4 payments).
Products named: Emrelis
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valley Medical Center, WA $1,060
- Mgpo Radiology Associates $905
- $781
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.